ADVERTISEMENT
4 /5 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Finance

Janssen invests in retinal disease firm MeiraGTx

by Michael McCoy
February 8, 2019 | APPEARED IN VOLUME 97, ISSUE 6

 

Johnson & Johnson’s Janssen Pharmaceuticals is putting $100 million into MeiraGTx, a London-based developer of gene therapies for retinal and other diseases. The firm uses adeno-associated viruses to deliver corrective genes to the eye, salivary gland, and central nervous system. Janssen and MeiraGTx will work on treatments, now in clinical trials, for the eye diseases achromatopsia and X-linked retinitis pigmentosa.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment